Abstract
In patients treated with macitentan (Opsumit_, Actelion Pharmaceuticals Ltd., Basel, Switzerland) for pulmonary arterial hypertension (PAH), prevention and/or effective management of treatment-related adverse events may improve adherence. However, management of these adverse events can be challenging and the base of evidence and clinical experience for macitentan is limited. In the absence of evidence, consensus recommendations from physicians experienced in using macitentan to treat PAH may benefit patients and physicians who are using macitentan. Consensus recommendations were developed by a panel of physicians experienced with macitentan and PAH using a modified Delphi process. Over three iterations, panelists developed and refined a series of statements on the use of macitentan in PAH and rated their agreement with each statement on a Likert scale. The panel of 18 physicians participated and developed a total of 118 statements on special populations, add-on therapy, drug-drug interactions, warnings and precautions, hospitalization and functional class, and adverse event management. The resulting consensus recommendations are intended to provide practical guidance on real-world issues in using macitentan to treat patients with PAH.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 702-711 |
| Number of pages | 10 |
| Journal | Pulmonary Circulation |
| Volume | 7 |
| Issue number | 3 |
| DOIs | |
| State | Published - 2017 |
Fingerprint
Keywords
- Adverse events
- Endothelin receptor antagonist
- Therapy adherence
ASJC Scopus subject areas
- Pulmonary and Respiratory Medicine
Cite this
Recommendations for the clinical management of patients receiving macitentan for pulmonary arterial hypertension (PAH) : A Delphi consensus document. / Rahaghi, Franck F.; Alnuaimat, Hassan M.; Awdish, Rana L.A.; Balasubramanian, Vijay P.; Bourge, Robert C.; Burger, Charles Dwayne; Butler, John; Gregory Cauthen, C.; Chakinala, Murali M.; deBoisblanc, Bennett P.; Eggert, Michael S.; Engel, Peter; Feldman, Jeremy; Wesley McConnell, J.; Park, Myung; Sager, Jeffrey S.; Sood, Namita; Palevsky, Harold I.
In: Pulmonary Circulation, Vol. 7, No. 3, 2017, p. 702-711.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Recommendations for the clinical management of patients receiving macitentan for pulmonary arterial hypertension (PAH)
T2 - A Delphi consensus document
AU - Rahaghi, Franck F.
AU - Alnuaimat, Hassan M.
AU - Awdish, Rana L.A.
AU - Balasubramanian, Vijay P.
AU - Bourge, Robert C.
AU - Burger, Charles Dwayne
AU - Butler, John
AU - Gregory Cauthen, C.
AU - Chakinala, Murali M.
AU - deBoisblanc, Bennett P.
AU - Eggert, Michael S.
AU - Engel, Peter
AU - Feldman, Jeremy
AU - Wesley McConnell, J.
AU - Park, Myung
AU - Sager, Jeffrey S.
AU - Sood, Namita
AU - Palevsky, Harold I.
PY - 2017
Y1 - 2017
N2 - In patients treated with macitentan (Opsumit_, Actelion Pharmaceuticals Ltd., Basel, Switzerland) for pulmonary arterial hypertension (PAH), prevention and/or effective management of treatment-related adverse events may improve adherence. However, management of these adverse events can be challenging and the base of evidence and clinical experience for macitentan is limited. In the absence of evidence, consensus recommendations from physicians experienced in using macitentan to treat PAH may benefit patients and physicians who are using macitentan. Consensus recommendations were developed by a panel of physicians experienced with macitentan and PAH using a modified Delphi process. Over three iterations, panelists developed and refined a series of statements on the use of macitentan in PAH and rated their agreement with each statement on a Likert scale. The panel of 18 physicians participated and developed a total of 118 statements on special populations, add-on therapy, drug-drug interactions, warnings and precautions, hospitalization and functional class, and adverse event management. The resulting consensus recommendations are intended to provide practical guidance on real-world issues in using macitentan to treat patients with PAH.
AB - In patients treated with macitentan (Opsumit_, Actelion Pharmaceuticals Ltd., Basel, Switzerland) for pulmonary arterial hypertension (PAH), prevention and/or effective management of treatment-related adverse events may improve adherence. However, management of these adverse events can be challenging and the base of evidence and clinical experience for macitentan is limited. In the absence of evidence, consensus recommendations from physicians experienced in using macitentan to treat PAH may benefit patients and physicians who are using macitentan. Consensus recommendations were developed by a panel of physicians experienced with macitentan and PAH using a modified Delphi process. Over three iterations, panelists developed and refined a series of statements on the use of macitentan in PAH and rated their agreement with each statement on a Likert scale. The panel of 18 physicians participated and developed a total of 118 statements on special populations, add-on therapy, drug-drug interactions, warnings and precautions, hospitalization and functional class, and adverse event management. The resulting consensus recommendations are intended to provide practical guidance on real-world issues in using macitentan to treat patients with PAH.
KW - Adverse events
KW - Endothelin receptor antagonist
KW - Therapy adherence
UR - http://www.scopus.com/inward/record.url?scp=85032348172&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85032348172&partnerID=8YFLogxK
U2 - 10.1177/2045893217721695
DO - 10.1177/2045893217721695
M3 - Article
AN - SCOPUS:85032348172
VL - 7
SP - 702
EP - 711
JO - Pulmonary Circulation
JF - Pulmonary Circulation
SN - 2045-8932
IS - 3
ER -